Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system.
Clasp Therapeutics has raised $150.0M in total funding. The most recent round was Series A. The last funding was announced in March 2024.
Clasp Therapeutics's investors include Vivo Capital, Catalio Capital Management, Blackbird Ventures, Novo Holdings, Cure Ventures.
Clasp Therapeutics is headquartered in Cambridge, United States.
Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system.
Clasp Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Clasp Therapeutics — Funding & Investors." VCBacked, March 20, 2024, https://www.vcbacked.co/company/clasp-therapeutics. Accessed July 21, 2026.
VCBacked. (2024). Clasp Therapeutics — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/clasp-therapeutics
{{cite web |title=Clasp Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/clasp-therapeutics |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated